Lymphedema — Symptoms, Causes & Treatment | MyMedicPlus

Lymphedema (lymphoedema) is a chronic, progressive condition of lymphatic system insufficiency causing accumulation of protein-rich interstitial fluid in the subcutaneous tissues, leading to soft tissue swelling, fibrosis, chronic inflammation, and significant functional impairment. The lymphatic system normally drains interstitial fluid, protein, lipids, and immune cells back to the bloodstream — when lymphatic vessels are damaged, obstructed, or developmentally absent, this drainage fails and fluid accumulates causing progressive swelling, skin changes, and disability. Lymphedema affects approximately 250 million people worldwide — making it one of the most prevalent chronic conditions globally — and is classified as primary (from congenital lymphatic developmental abnormality) or secondary (from acquired lymphatic damage). Secondary lymphedema from cancer treatment is the most common form in high-income countries: it develops in 15-40% of breast cancer survivors after axillary lymph node dissection plus radiotherapy, 20-30% of gynaecological cancer survivors, and 30-40% of patients with melanoma or head-and-neck cancer following lymph node surgery. In low-income countries, filariasis (parasitic infection with Wuchereria bancrofti) is the most common cause — affecting 120 million people globally. Lymphedema is currently incurable but highly manageable with complex decongestive therapy (CDT), compression garments, and exercise. Without treatment, fluid protein content stimulates fibroblast proliferation, causing progressive tissue fibrosis, skin thickening, and increased infection (cellulitis) risk — ultimately leading to elephantiasis in end-stage neglected disease.

Primary lymphedema arises from congenital lymphatic developmental anomalies: lymphatic aplasia (absent lymphatic vessels), hypoplasia (reduced lymphatic vessel number or calibre), or lymphatic valve incompetence. Primary forms are classified by age of onset — congenital lymphedema praecox (Milroy disease: autosomal dominant, FLT4/VEGFR3 mutation, presenting at birth or in infancy with bilateral lower limb swelling); lymphedema tarda (onset after age 35); and GATA2 deficiency (associated with lymphedema, myelodysplasia, NK/B cell deficiency). Secondary lymphedema from acquired lymphatic disruption: cancer surgery — axillary lymph node dissection (ALND) for breast cancer is the most common cause in Western countries, with sentinel node biopsy substantially reducing lymphedema risk (5-7%) compared to ALND (15-40%); pelvic lymph node dissection (gynaecological cancers, prostate cancer, bladder cancer, melanoma staging); radiotherapy — radiation-induced fibrosis of lymphatic channels and lymph nodes causes delayed-onset lymphedema months to years post-treatment; tumour compression or infiltration of lymphatic vessels causing lymphatic obstruction; infection — filariasis (Wuchereria bancrofti, Brugia malayi — the most common cause of lymphedema globally, affecting 120 million, endemic in South Asia, sub-Saharan Africa, Pacific Islands — filarial worms lodge in lymphatic vessels causing progressive obstruction and inflammatory damage); recurrent cellulitis — each episode of skin infection further damages lymphatic vessels, creating a self-amplifying cycle; chronic venous insufficiency (phlebolymphedema — combined venous and lymphatic failure); obesity (BMI above 40 is an independent risk factor for lymphedema through mechanical and inflammatory mechanisms); and trauma or surgery directly damaging lymphatic drainage routes.

Lymphedema most commonly affects a limb — lower limb in primary lymphedema and lower extremity gynaecological cancer-related lymphedema; upper limb in breast cancer-related lymphedema — but can affect any body part including the head, neck, genitalia, or trunk. The cardinal symptom is painless swelling initially, though the affected limb progressively develops heaviness, tightness, aching, and reduced range of motion as the condition advances and fibrosis develops. Clinical staging (International Society of Lymphology, ISL): Stage 0 (latent) — subclinical lymphatic impairment without visible oedema, detectable only with specialised imaging; Stage I — pitting oedema that reduces with limb elevation; Stage II — non-pitting oedema that does not reduce with elevation (early fibrosis); Stage III — lymphostatic elephantiasis with severe non-pitting oedema, gross skin thickening, skin folds, papillomatosis, and hyperkeratosis. Positive Stemmer's sign — inability to pinch the skin at the base of the second toe or finger — is pathognomonic for lymphedema (though absent in early stages). Skin changes that develop progressively: loss of skin texture and elasticity; dependent erythema (redness); warty skin thickening (verrucous hyperkeratosis — 'cobblestone' skin); peau d'orange (orange-peel texture from dermal lymphatic involvement); skin fold deepening ('buffalo hump' at the ankle); and pachyonychia (thickened, yellow nails). Diurnal variation is characteristic in early stages — swelling typically worse by evening and improves overnight with limb elevation. Lymphedema causes profound psychosocial impact: depression, anxiety, body image distress, and social isolation are common from the visible, chronic nature of the condition.

Lymphedema is primarily a clinical diagnosis based on history (cancer treatment, family history, onset pattern) and examination (characteristic oedema distribution, positive Stemmer's sign, skin changes, ISL staging). Limb volume measurement using sequential circumferential measurements (using a perometer optical volumetry device or tape-measure calculated with the truncated cone formula) establishes baseline and monitors treatment response — a 10% volume difference between limbs is clinically significant. Imaging investigations to confirm diagnosis or assess lymphatic anatomy: lymphoscintigraphy (nuclear medicine scan using technetium-99m labelled colloid injected intradermally) — the gold standard for confirming lymphatic system dysfunction, demonstrating dermal backflow, absent or delayed lymphatic uptake, absent lymph nodes, and lymphatic collateral pathways; indocyanine green (ICG) near-infrared fluorescence lymphography — a sensitive, real-time imaging modality visualising superficial lymphatic vessels and identifying pre-clinical functional impairment; MRI lymphangiography — provides detailed anatomical information on lymphatic vessel and lymph node morphology for surgical planning (lymph node transfer, lymphaticovenous anastomosis); duplex ultrasound — excludes deep vein thrombosis as a cause of acute limb swelling (important differential diagnosis in cancer patients). CT scanning of the abdomen and pelvis assesses for tumour recurrence causing lymphatic obstruction in cancer survivors presenting with new lower limb lymphedema. Blood tests: FBC (eosinophilia in filariasis), filarial antigen test and night blood smear (in endemic regions), serum albumin and protein (hypoalbuminaemia causing systemic oedema is a differential).

Lymphedema has no cure, but complex decongestive therapy (CDT) — the gold standard treatment — significantly reduces limb volume, prevents progression, and substantially improves quality of life. CDT comprises four components: (1) Manual Lymphatic Drainage (MLD): a specialised gentle skin-stretching massage technique performed by a trained lymphedema therapist, working proximally (stimulating deep lymph nodes) before working distally — redirecting lymph flow through collateral pathways and restoring lymphatic contractility; typically delivered in 45-60 minute sessions daily for 4-6 weeks (intensive treatment phase); (2) Multi-layer, short-stretch compression bandaging: applied daily during the intensive phase to reduce limb volume — short-stretch bandages provide high working pressure during movement and low resting pressure, supporting muscle pump function without restricting venous return; (3) Decongestive exercises: prescribed limb movements during compression bandaging drive the lymphatic muscle pump; (4) Skin care: meticulous daily skin hygiene with bland emollient, nail care, and avoidance of injury to reduce infection (cellulitis) risk. The intensive phase is followed by the maintenance phase: transition to compression garments (Class II or III flat-knit compression stockings/sleeves — custom-fitted to the post-treatment limb measurement, replaced every 6 months); daily MLD self-massage as instructed; ongoing exercise and skin care. Pneumatic compression pumps (sequential compression devices) as an adjunct to CDT in severe or refractory lymphedema — provide additional volume reduction during home therapy. Surgical options for selected patients with refractory or severe disease: Lymphaticovenous anastomosis (LVA) — microsurgical connection of lymphatic vessels to small venules, most effective in early-stage disease (ISL Stage I-IIA) before fibrosis develops; vascularised lymph node transfer (VLNT) — harvesting and transplanting lymph node tissue from a donor site (groin, supraclavicular, lateral thoracic) to the affected region; liposuction — for non-pitting fibroadipose stage III lymphedema not responding to CDT, requires lifelong compression post-procedure. Filariasis treatment: diethylcarbamazine (DEC), ivermectin, or albendazole — effective against microfilariae and some adult worms; WHO mass drug administration in endemic communities.

Acute and recurrent cellulitis is the most serious and common complication of lymphedema — the protein-rich lymphatic fluid provides an ideal bacterial culture medium, and loss of normal lymphatic immune surveillance removes a critical infection barrier; each episode of cellulitis further damages lymphatic vessels, worsening lymphedema severity and creating a self-perpetuating cycle. Cellulitis typically presents as a rapidly spreading area of erythema, warmth, swelling, and systemic features (fever, rigors, tachycardia) — requiring prompt antibiotic treatment (IV flucloxacillin or amoxicillin for mild-moderate; piperacillin-tazobactam for severe) and temporary compression reduction. Patients with 3 or more episodes per year benefit from prophylactic phenoxymethylpenicillin (penicillin V) 250-500mg twice daily. Lymphangiosarcoma (Stewart-Treves syndrome): a rare but feared malignant complication of chronic longstanding lymphedema (particularly post-mastectomy lymphedema present for 10+ years) — a high-grade vascular sarcoma arising within the lymphedematous tissue, presenting as blue-red skin lesions progressing rapidly; carries extremely poor prognosis with median survival under 19 months despite aggressive surgery. Progressive fibrosis leads to irreversible elephantiasis in neglected end-stage lymphedema — gross limb enlargement, skin changes, and complete loss of limb function. Functional and psychosocial complications are profound: inability to wear normal clothing or shoes, restricted daily activities, reduced employment capacity, depression (40-50%), anxiety, impaired sexual function, and social withdrawal from body image concerns.

Prevention of cancer treatment-related lymphedema begins before surgery: sentinel lymph node biopsy (SLNB) where oncologically appropriate substantially reduces lymphedema risk compared to full axillary lymph node dissection (5-7% vs 15-40% for breast cancer) — patients eligible for SLNB should be offered this whenever oncologically safe. Axillary reverse mapping during ALND aims to preserve lymphatic channels draining the arm while removing oncological tissue. LYMPHA (Lymphatic Microsurgical Preventive Healing Approach): immediate LVA performed at the time of ALND may reduce future lymphedema development by immediately restoring lymphatic drainage continuity. Patient education after cancer lymph node surgery: graduated return to upper limb activities including resistance exercise (RCT evidence shows upper body resistance exercise does not increase lymphedema risk in breast cancer survivors — the REACT and PAL trials); avoid injury, burns, blood pressure cuffs, and blood draws in the at-risk limb; maintain healthy weight (obesity substantially increases lymphedema risk); seek immediate medical attention for any signs of cellulitis (redness, warmth, swelling with fever). Skin protection: emollient moisturisers daily, prompt treatment of any skin breaks or abrasions, nail care, insect repellent to reduce mosquito bites in endemic areas. Regular lymphedema monitoring with limb volume measurements at cancer follow-up appointments — early bioimpedance spectroscopy (BIS) screening allows intervention at subclinical Stage 0 before overt oedema develops (evidence shows compression garments at Stage 0 prevent progression in 50-70%). For filariasis prevention: DEET-containing insect repellent, bed nets, and preventive chemotherapy with DEC in endemic regions.

Seek emergency medical attention for: rapidly spreading redness, warmth, and swelling of a lymphedematous limb with fever and systemic illness (cellulitis — may progress to sepsis without prompt antibiotic treatment); sudden acute limb swelling in a cancer survivor (must exclude deep vein thrombosis and tumour recurrence causing lymphatic obstruction — requires urgent Doppler ultrasound and oncological review). See a lymphedema specialist or GP as soon as possible for: new swelling in a limb after cancer surgery (axillary, pelvic, or inguinal lymph node dissection) or radiotherapy — even months or years after treatment; any new persistent asymmetric limb swelling without obvious cause (lower limb in a young woman warrants consideration of primary lymphedema — Stemmer's sign, lymphoscintigraphy); a positive Stemmer's sign detected by self-examination (inability to pinch the skin at the base of a toe or finger in the affected limb). Early referral to a specialist lymphedema therapist trained in CDT is critical — the sooner CDT is started, the more reversible the condition; once fibrosis becomes established (Stage II-III), volume reduction is more difficult and maintenance becomes the primary goal. All breast cancer, gynaecological cancer, and melanoma survivors should be informed of their lifetime risk of lymphedema and the importance of early reporting of swelling at cancer follow-up appointments.